SYG(SZ:300740) Xin Jing Bao·2025-04-30 08:38Core Viewpoint - The high-end transformation of Shuiyang Group is facing challenges, as evidenced by a significant decline in revenue and profit in the 2024 annual report, raising questions about whether this strategy is beneficial or detrimental to the company [1]. Financial Performance - Shuiyang Group reported a revenue of 4.237 billion yuan in 2024, a year-on-year decrease of 5.69% [1]. - The net profit attributable to shareholders fell by 62.63% to 110 million yuan, while the non-recurring net profit decreased by 56.74% to 118 million yuan [1]. - Sales expenses increased by 11.89% to 2.079 billion yuan, accounting for 49.07% of total revenue [6]. Business Strategy - The company is transitioning to become a "global new luxury beauty group," which involves restructuring its business and increasing investment in high-end brands [1][2]. - Shuiyang Group has made significant acquisitions, including the purchase of the French luxury skincare brand EDB for over 300 million yuan and the acquisition of the American luxury skincare brand RéVive [2][3]. Product Performance - Revenue from self-owned brands reached 1.651 billion yuan, representing approximately 38.97% of total revenue, with a gross margin of 74.27% [3]. - All product categories, including creams, masks, and brand management services, experienced revenue declines, with creams generating 3.351 billion yuan (down 4.38%) and masks generating 734 million yuan (down 10.8%) [4][5]. Research and Development - R&D expenses increased by only 7.32% to 82.1755 million yuan, indicating a lower investment compared to sales expenses [7]. - The company has established a stock incentive plan, but it failed to meet performance targets, resulting in the cancellation of unvested shares for 258 individuals [7][8].